UOC
GTHX icon

UBS O'Connor’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

UBS O'Connor’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-164,374
Closed -$893K – 747
2022
Q4 		$893K Buy
+164,374
New +$1.38M 0.02% 574
2018
Q4 		– Sell
-65,000
Closed -$3.4M – 304
2018
Q3 		$3.4M Buy
+65,000
New +$3.54M 0.08% 139

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS O'Connor's GTHX Position: Q1 2023 in Review

UBS O'Connor sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 164,374 shares — an estimated $893K sold.

UBS O'Connor first reported a position in GTHX in Q3 2018 and held it in 2 quarters. The position peaked at $3.4M in Q3 2018. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

  • UBS O'Connor reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • UBS O'Connor sold 164,374 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $893K.
  • UBS O'Connor first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • UBS O'Connor's G1 Therapeutics, Inc. Common Stock position peaked at $3.4M in Q3 2018.
  • 96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on UBS O'Connor's 13F filing for Q1 2023, filed 15 May 2023.